OsteoSight Hip
Overview
OsteoSight™ is an AI-driven software developed by Naitive Technologies to transform orthopedic care by enabling the opportunistic assessment of bone mineral density (BMD) from routine X-rays. It is specifically designed to analyze standard anteroposterior (AP) radiographs of the hip or pelvis in patients aged 50 years and older. The tool identifies cases at risk for low BMD, which is a key indicator of osteoporosis, a condition often undiagnosed until a fracture occurs.
By seamlessly integrating into existing orthopedic and radiology workflows, OsteoSight™ provides a notification in the form of a report to aid interpreting physicians in identifying patients with possible low BMD at the femoral neck. This early identification prompts a clinical assessment of bone health, supporting earlier interventions, improved surgical planning, and ultimately enhancing patient outcomes. The technology has received FDA 510(k) clearance (K251408) and was designated an FDA Breakthrough Device in 2023, with its diagnostic accuracy, reproducibility, and robustness validated in peer-reviewed research. OsteoSight™ aims to address the urgent unmet clinical need in osteoporosis management, allowing orthopedic practices to take a proactive role and potentially expand their services.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- Opportunistic assessment of bone mineral density (BMD) from routine X-rays
- Analyzes hip or pelvis X-rays in patients 50 years and older
- Identifies cases at risk for low BMD
- Provides a notification/report to aid interpreting physician
- Integrates into existing orthopedic and radiology workflows
- Validated in peer-reviewed research for diagnostic accuracy and reproducibility
- AI-driven software for musculoskeletal health
- Aids in earlier diagnosis and intervention for osteoporosis
- Excludes unsuitable cases including incorrect body parts, metalwork, and unacceptable femur positioning
Use Cases
- Early identification of patients at risk for osteoporosis
- Opportunistic bone health assessment during routine X-rays for other clinical concerns
- Streamlining referrals for comprehensive bone health assessment
- Supporting earlier interventions and improved surgical planning
- Expanding services and capturing ancillary revenue for orthopedic practices
- Improving patient outcomes by reducing osteoporotic fractures
What Physicians Need to Know
OsteoSightu2122 Hip is an AI-enabled tool for opportunistic assessment of low BMD in patients 50 years and older using routine hip/pelvis X-rays. It provides a notification to aid in identifying at-risk patients, prompting further clinical assessment of bone health. It is crucial to remember that OsteoSightu2122 does not provide a diagnosis or treatment recommendation and should not be used to rule out low BMD. Physicians should continue to follow recommended screening and assessment practices, and consider additional evaluations like comprehensive fracture risk assessments in conjunction with the tool's insights. This technology aims to enable earlier intervention and improve surgical planning by identifying previously unnoticed patients with poor bone health.
OsteoSightu2122 Hip is built for seamless integration into existing clinical workflows. It operates by integrating with a host platform to securely transfer DICOM images and associated metadata from current clinical imaging systems. The generated reports for positive cases can be sent directly back to the Picture Archiving and Communication System (PACS) for physician interpretation or accessed through a browser-based interface.
Details
| Category | Clinical Decision Support & Reference, Radiology & Imaging AI |
| Pricing | Contact for pricing |
| Deployment | Cloud-based, with integration capabilities for clinical imaging systems (e.g., PACS) for secure DICOM image transfer. |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
1 AI-estimated OsteoSight™ received 510(k) clearance from the U.S. Food and Drug Administration (FDA) on September 2, 2025, under K251408. It was also designated an FDA Breakthrough Device in 2023. |
| Integrations | |
| EHR | Not specified |
| Specialties | Endocrinology, Orthopedics, Radiology |
What the Web Says
OsteoSightu2122 Hip, developed by Naitive Technologies, is an AI-enabled software that analyzes routine hip and pelvic X-rays to identify patients aged 50 and older at risk for low bone mineral density (BMD), a key indicator of osteoporosis. It provides a report to physicians to aid in clinical assessment and prompt earlier intervention. The device received FDA 510(k) clearance in September 2025 and was previously designated as an FDA Breakthrough Device in 2023.
Overall: PositiveStrengths
- Opportunistically identifies patients at risk of low BMD from routine X-rays, potentially increasing early diagnosis rates.
- Integrates seamlessly into existing orthopedic workflows.
- High diagnostic accuracy, reproducibility, and robustness across various clinical confounders and X-ray hardware.
- Aids in earlier intervention, improving surgical planning and patient outcomes.
- Addresses the significant problem of underdiagnosed osteoporosis.
- FDA 510(k) cleared and designated as a Breakthrough Device.
Limitations
- Specificity of 0.852 and sensitivity of 0.628, while meeting pre-specified criteria, suggest there's room for improvement in identifying all true positives without increasing false positives.
- Relatively new to the market (FDA clearance in September 2025), so long-term real-world data and extensive user reviews may still be emerging.
Based on reviews from: My Framer Site (Naitive Press Release), PMC (PubMed Central), ResearchGate, Femtech Insider, PubMed, FDA, Nyquist AI Blog
Last updated: 2026-07-18
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate OsteoSight Hip
Press & Coverage
Videos
Product demos, reviews, and walkthroughs for OsteoSight Hip.
